<DOC>
	<DOCNO>NCT01542190</DOCNO>
	<brief_summary>The purpose study compare effect preoperative postoperative use topical ketorolac tromethamine 0.4 % versus placebo uncomplicated cataract surgery . Patients schedule undergo phacoemulsification randomize receive either topical prednisolone acetate 1 % 4 time daily ( QID ) plus dextran 70/hypromellose QID ( placebo group ) topical prednisolone 1 % QID plus ketorolac tromethamine 0.4 % QID ( ketorolac group ) three day preoperatively four week postoperatively . The primary outcome 5 week surgery angiographic cystoid macular edema .</brief_summary>
	<brief_title>Comparison Topical Ketorolac 0,4 % Versus Placebo Cataract Surgery</brief_title>
	<detailed_description>Purpose : To compare effect preoperative postoperative use topical ketorolac tromethamine 0.4 % versus placebo uncomplicated cataract surgery . Methods : This mask single-center , randomize clinical study comprise 80 patient undergoing phacoemulsification cataract surgery . Patients schedule undergo phacoemulsification recognize cystoid macular edema ( CME ) risk ( diabetic retinopathy , retinal vascular disease macular abnormality ) randomize receive either topical prednisolone acetate 1 % 4 time daily ( QID ) plus dextran 70/hypromellose QID ( placebo group ; n=40 ) topical prednisolone 1 % QID plus ketorolac tromethamine 0.4 % QID ( ketorolac group ; n=40 ) three day preoperatively four week postoperatively . In group topical gatifloxacin administer treat eye QID , start three day surgery continue seven day . The primary outcome 5 week surgery angiographic cystoid macular edema . Other include outcomes best correct visual acuity ( BCVA ) , intraocular pressure ( IOP ) , CME incidence , retinal thickness measure spectral-domain optical coherence tomography ( OCT ) .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Subjects nuclear cataract , density 1 2 classify LOCS II , schedule undergo phacoemulsification cataract surgery . Patients : Diabetes , Hypertension , uveitis , macular disease , congenital ocular abnormality , cataract density 0 3 LOCS II , pseudoexfoliation syndrome . Patients treatment nonsteroidal antinflammatory drug topical eye drop exclude .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>cataract surgery</keyword>
	<keyword>cystoid macular edema</keyword>
	<keyword>angiography</keyword>
</DOC>